Radio frequency ablation for primary liver cancer: an evidence-based analysis
Record ID 32004000756
English
Authors' objectives:
This study aims to provide an evidence-based analysis on the effectiveness and cost-effectiveness of radio frequency ablation (RFA) for hepatocellular carcinoma (HCC), or primary liver cancer.
Authors' recommendations:
RFA is effective for treating patients with small unresectable HCC.
Level 2 evidence suggests RFA is as safe and perhaps more effective than PEI to treat HCC.
RFA and PEI are more effective and more cost-effective than TACE.
RFA is marginally more expensive, yet more cost-effective than PEI.
Complications are few, but experienced interventional radiologists should do RFA.
RFA may benefit some patients with liver metastases or other primary cancer in other sites, however effectiveness for these indications has not yet been established. Randomized control trials that focus on RFA in these other cancer areas are currently underway.
Authors' methods:
Systematic review
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.health.gov.on.ca/english/providers/program/mas/tech/reviews/pdf/rev_rfa_060104.pdf
URL for additional information:
http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations/ohtas-reports-and-ohtac-recommendations/radiofrequency-ablation-for-primary-liver-cancer
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Carcinoma, Hepatocellular
- Catheter Ablation
- Costs and Cost Analysis
- Liver Neoplasms
Contact
Organisation Name:
Medical Advisory Secretariat
Contact Address:
Medical Advisory Secretariat, 20 Dundas Street West, 10th Floor, Toronto, ON M5G 2N6 CANADA. Tel: 416-314-1092l; Fax: 416-325-2364;
Contact Name:
MASinfo.moh@ontario.ca
Contact Email:
MASinfo.moh@ontario.ca
Copyright:
Medical Advisory Secretariat, Ontario Ministry of Health and Long-Term Care
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.